Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Step Pharma logo — Developing selective inhibitors of CTPS1 for patients with c...

Step Pharma

Developing selective inhibitors of CTPS1 for patients with cancer and auto-immune diseases

Founded 2014 France France 14 employees Series B Total: $52.00M Biotechnology, Pharmaceutical

General Information

Company Name Step Pharma
Founded Year 2014
Location France France
Employees 14
Industries Biotechnology, Pharmaceutical
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with Step Pharma. To contact Step Pharma, visit step-ph.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Step Pharma compare?

A PDF of Step Pharma and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Step Pharma soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Step Pharma

Step Pharma is a France-based biotechnology and pharmaceutical company, founded in 2014, that specializes in developing selective inhibitors of CTPS1 (cytidine triphosphate synthase 1) for the treatment of cancer and autoimmune diseases. The company's lead program, dencatistat (STP938), is a potent, selective, oral inhibitor of CTPS1 with demonstrated anti-tumor activity. In 2022, Dencatistat entered clinical development in a PhI/II study for the treatment of relapsed and refractory T-cell and B-cell lymphoma. The company has also initiated a solid tumor study focused on ovarian cancer using the concept of synthetic lethality and biomarker selection of patients. Step Pharma's recent Series B investment at 24 March 2021 amounted to €35.00M and included investors such as Bpifrance, Kurma Partners, Pontifax, Sunstone Capital, and Hadean Partners. Step Pharma's innovative approach and promising lead program position the company as a key player in the development of novel treatments for challenging diseases.

Business keywords: CTPS1 inhibitors, oncology, autoimmune diseases, biopharmaceuticals, clinical development, cancer therapy, biomarker selection, genetic immunodeficiencies research, synthetic lethality, biotech research, biomarker-driven therapy, drug discovery, tumor agnostic approach, immunotherapy, venture-backed biotech

Services & Products

Development of targeted oncology therapies

Target Customers

Patients with various cancer types

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series B €35.00M 5
Bpifrance Kurma Partners Pontifax
Bpifrance, Kurma Partners +3
24 Mar 2021
Series A €14.50M 5
Bpifrance IDInvest Partners Kurma Partners
Bpifrance, IDInvest Partners +3
21 Nov 2017
Seed Round €2.50M -
02 Jul 2014

Step Pharma Alternatives & Competitors

View All Alternatives
Step Pharma vs
Odyssey Therapeutics
Odyssey Therapeutics

Building a machine learning-based platform to develop novel therapeutics focusing on cancer and auto...

IPO
127 employees
Biotechnology, Pharmaceutical
Step Pharma vs
ROME Therapeutics
ROME Therapeutics United States

Harnessing the power of the repeatome to develop a new class of therapies for cancer and autoimmune...

Acquired
16 employees
Biotechnology, Health Care
Step Pharma vs
Kanaph Therapeutics
Kanaph Therapeutics Korea South

We are the leader of next generation immuno-oncology and autoimmune diseases.

Series B
16 employees
Biotechnology, Pharmaceutical
View all alternatives

FAQ About Step Pharma

Developing selective inhibitors of CTPS1 for patients with cancer and auto-immune diseases
Step Pharma was founded in 2014.
Step Pharma is headquartered in France.
Step Pharma operates in Biotechnology and Pharmaceutical. Its work centres on CTPS1 inhibitors, oncology, autoimmune diseases and biopharmaceuticals. Its customers include Patients with various cancer types.
Step Pharma has approximately 14 employees.
Step Pharma has completed 3 funding rounds, raising a total of $52.00M. The latest funding stage is Series B.
Step Pharma offers: Development of targeted oncology therapies.
Top alternatives and competitors to Step Pharma include Odyssey Therapeutics, ROME Therapeutics, Kanaph Therapeutics, Sareum Ltd, OncXerna Therapeutics . These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Step Pharma and Odyssey Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Step Pharma, https://bouncewatch.com/company/step-pharma, updated 7 June 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes